Bidirectional interplay between the gut microbiota and GLP-1 receptor agonists: towards Microbiome-Mediated therapeutics in type 2 diabetes mellitus

Key Points

• GLP-1 receptor agonists influence gut microbiota composition, impacting metabolic health.
• Higher diversity in gut microbiota positively correlates with better responses to GLP-1 therapies.
• Assessment using cross-sectional studies of individuals with type 2 diabetes highlights significant interactions.
• These findings suggest that manipulating gut microbiota could enhance therapeutic outcomes for diabetes management.